Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815899 | 1.00 | HSD11B1 (0.44) | HSD11B1TP53MCHR1MEN1KMT2A | |
| SCHEMBL14815583 | 0.93 | SCN3A (0.38) | HSD11B1TP53MCHR1MEN1KMT2A | |
| SCHEMBL15462460 | 0.93 | SCN3A (0.38) | HSD11B1TP53MCHR1MEN1KMT2A | |
| SCHEMBL14815581 | 0.91 | KDM4E (0.41) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL14816147 | 0.91 | KDM4E (0.41) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL14815434 | 0.91 | KDM4E (0.41) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL14815545 | 0.90 | SMN1; SMN2 (0.44) | MEN1KMT2ALMNAGAAPOLB | |
| SCHEMBL15462439 | 0.90 | SMN1; SMN2 (0.44) | MEN1KMT2ALMNAGAAPOLB | |
| SCHEMBL15462425 | 0.90 | MCHR1 (0.35) | HSD11B1MCHR1GAA | |
| SCHEMBL14815848 | 0.90 | MCHR1 (0.35) | HSD11B1MCHR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | HSD11B1 3627/4885TP53 2892/4885MCHR1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.